Renaparin® in Kidney Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 14, 2019

Primary Completion Date

April 21, 2020

Study Completion Date

April 21, 2020

Conditions
Delayed Graft Function
Interventions
DRUG

Renaparin

50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation

DRUG

Placebo

50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation

Trial Locations (3)

14186

Department of Transplantation Surgery, Karolinska University Hospital, Huddinge, Stockholm

41345

Transplantationscentrum, Sahlgrenska University Hospital, Gothenburg

75185

Department of Surgical Sciences, Section of Transplantation Surgery, Uppsala University Hospital, Uppsala

Sponsors
All Listed Sponsors
lead

Corline Biomedical AB

INDUSTRY